EUVIMEDEUVIMED entdecken
Crossref

Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT

Guillaume Marquis-Gravel, Davide Cao, Dylan Taylor, Stuart J Pocock, Angelo Oliva, Samantha Sartori, Giulio G Stefanini, Philip Urban, Olivier Varenne, Stephan Windecker, Pieter C Smits, Marco Valgimigli und 2 weitere

JACC: Cardiovascular Interventions · 2026-07 · 19 (14) · 1910-1922

DOI: 10.1016/j.jcin.2026.05.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-07. Verfasst von Guillaume Marquis-Gravel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Hemorrhage, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Understanding the concomitant evolution of bleeding vs ischemic risk after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) treated with 1-month dual antiplatelet therapy (DAPT) would help optimize dynamic treatment strategies. OBJECTIVES: The aim of this study was to describe the timing of bleeding and ischemic events during 1 year after PCI in this population. METHODS: Timings of major bleeding events and of major adverse cardiovascular events (MACE) were analyzed in patient-level data from 7 prospective studies including HBR patients treated with PCI and 1-month DAPT. RESULTS: Among 7,266 patients (mean age 76 ± 9.0 years, 31.5% women), Bleeding Academic Research Consortium (BARC) types 3 to 5 bleeding occurred in 284 (4.0%), with 73 (1.0%) occurring ≤30 days after and 211 (2.9%) >30 days after index PCI. MACE occurred in 433 patients (6.0%), among which 64 (0.9%) occurred ≤30 days after index PCI and 369 (5.1%) after 30 days. During the first 30 days, there was no significant difference between rates of MACE and BARC types 3 to 5 bleeding events (22.3% vs 25.7%; P = 0.407). However, MACE rates were significantly higher than rates of BARC types 3 to 5 bleeding between 31 and 90 days (7.2% vs 4.9%; P = 0.024) and between 91 and 365 days (5.3% vs 3.1%; P < 0.001) CONCLUSIONS: Among HBR patients undergoing PCI treated with 1-month DAPT, the risk for major bleeding and MACE is highest in the first 30 days. MACE remain consistently more frequent than bleeding after the first month, when event rates stabilize over time while on single antiplatelet therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhagePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsDual Anti-Platelet TherapyCoronary Artery DiseaseHumansFemaleTime FactorsRisk FactorsTreatment OutcomeRisk AssessmentMaleAgedDrug Administration ScheduleAged, 80 and over

Stichwörter der Autor:innen

antiplatelet therapybleedingcoronary artery diseasehigh bleeding riskmajor adverse cardiovascular event(s)percutaneous coronary intervention

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Cardiology, Humanitas Gavazzeni, Bergamo, Italy.
  • London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy; Cardio Center, IRCCS Humanitas Research Hospital, Milan, Italy.

Zitieren

APA

Marquis-Gravel, G., Cao, D., Taylor, D., Pocock, S. J., Oliva, A., Sartori, S., Stefanini, G. G., Urban, P., Varenne, O., Windecker, S., Smits, P. C., Valgimigli, M., Mehran, R., & Krucoff, M. W. (2026). Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT. JACC: Cardiovascular Interventions, 19(14), 1910-1922. https://doi.org/10.1016/j.jcin.2026.05.027

Vancouver

Marquis-Gravel G, Cao D, Taylor D, Pocock SJ, Oliva A, Sartori S, et al. Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT. JACC: Cardiovascular Interventions. 2026;19(14):1910-1922. doi:10.1016/j.jcin.2026.05.027

BibTeX
@article{MarquisGravel2026,
  author = {Marquis-Gravel, Guillaume and Cao, Davide and Taylor, Dylan and Pocock, Stuart J and Oliva, Angelo and Sartori, Samantha and Stefanini, Giulio G and Urban, Philip and Varenne, Olivier and Windecker, Stephan and Smits, Pieter C and Valgimigli, Marco and Mehran, Roxana and Krucoff, Mitchell W},
  title = {Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {14},
  pages = {1910--1922},
  doi = {10.1016/j.jcin.2026.05.027}
}
Kostenlos starten →